Control of Epstein–Barr virus reactivation by activated CD40 and viral latent membrane protein 1
Author(s) -
Barbara Adler,
Eveline Schaadt,
Bettina Kempkes,
Ursula ZimberStrobl,
Barbara Baier,
Georg W. Bornkamm
Publication year - 2001
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.221439999
Subject(s) - bzlf1 , lytic cycle , virus , biology , virology , epstein–barr virus , latent virus , viral replication , virus latency , viral entry , cd40 , viral protein , viral matrix protein , antibody dependent enhancement , herpesviridae , immunology , viral disease , cytotoxic t cell , genetics , in vitro
In humans, Epstein-Barr virus (EBV) establishes a persistent latent infection in peripheral resting B lymphocytes. Virus reactivation is highly restricted. Whereas in healthy humans the infection usually is benign, immunocompromised patients show an increased risk for EBV-associated malignancies, accompanied by an increase in virus replication and in the number of virus-infected cells. To search for viral and host factors regulating virus reactivation, we used conditionally EBV-immortalized B cells. We found that CD40-CD40 ligand interaction and the viral mimic of activated CD40, EBV latent membrane protein 1, suppress virus reactivation. Both inhibit anti-IgM or phorbolester-induced transcription of the viral immediate early protein BZLF1, which controls entry into the viral lytic cycle. The finding that latent membrane protein 1 and CD40 contribute to the regulation of latency may have important implications for the balance between EBV and its host in normal as well as in immunocompromised individuals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom